Could a diabetes drug shield your brain from stroke?

NCT ID NCT07282041

Recruiting now Disease control Sponsor: National University of Singapore Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether dulaglutide, a once-weekly diabetes injection, can improve blood flow in the brains of people with severely narrowed arteries. About 130 participants who recently had a mini-stroke or mild stroke will receive either standard care or dulaglutide plus standard care. Researchers will measure brain blood flow after one year and track strokes for two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dulaglutide (a weekly injection used for diabetes)
What this could lead to: If it works, this could offer a new way to improve brain blood flow and reduce stroke risk in people with narrowed brain arteries.
What could go wrong: This is an early-to-mid stage trial with only 130 participants, so results may not apply to everyone. The drug may not improve blood flow enough or could cause side effects like nausea.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRACRANIAL ATHEROSCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cerebral atherosclerosis intracranial arteriosclerosis ischemic stroke transient ischemic attack

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTRACRANIAL ATHEROSCLEROSIS STROKE, ISCHEMIC

Contacts and locations

Locations

National University Hospital
RECRUITING

Singapore, 119228, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.